Innoviva Total Assets 2010-2024 | INVA
Innoviva total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
Innoviva Annual Total Assets
(Millions of US $) |
| 2023 |
$1,244 |
| 2022 |
$1,231 |
| 2021 |
$926 |
| 2020 |
$1,000 |
| 2019 |
$725 |
| 2018 |
$548 |
| 2017 |
$367 |
| 2016 |
$379 |
| 2015 |
$409 |
| 2014 |
$522 |
| 2013 |
$681 |
| 2012 |
$369 |
| 2011 |
$259 |
| 2010 |
$331 |
| 2009 |
$181 |
Innoviva Quarterly Total Assets
(Millions of US $) |
| 2024-03-31 |
$1,268 |
| 2023-12-31 |
$1,244 |
| 2023-09-30 |
$1,188 |
| 2023-06-30 |
$1,118 |
| 2023-03-31 |
$1,130 |
| 2022-12-31 |
$1,231 |
| 2022-09-30 |
$1,328 |
| 2022-06-30 |
$1,138 |
| 2022-03-31 |
$1,107 |
| 2021-12-31 |
$926 |
| 2021-09-30 |
$887 |
| 2021-06-30 |
$789 |
| 2021-03-31 |
$1,088 |
| 2020-12-31 |
$1,000 |
| 2020-09-30 |
$922 |
| 2020-06-30 |
$880 |
| 2020-03-31 |
$788 |
| 2019-12-31 |
$725 |
| 2019-09-30 |
$676 |
| 2019-06-30 |
$642 |
| 2019-03-31 |
$590 |
| 2018-12-31 |
$548 |
| 2018-09-30 |
$278 |
| 2018-06-30 |
$339 |
| 2018-03-31 |
$277 |
| 2017-12-31 |
$367 |
| 2017-09-30 |
$391 |
| 2017-06-30 |
$372 |
| 2017-03-31 |
$392 |
| 2016-12-31 |
$379 |
| 2016-09-30 |
$371 |
| 2016-06-30 |
$378 |
| 2016-03-31 |
$388 |
| 2015-12-31 |
$409 |
| 2015-09-30 |
$438 |
| 2015-06-30 |
$462 |
| 2015-03-31 |
$489 |
| 2014-12-31 |
$522 |
| 2014-09-30 |
$554 |
| 2014-06-30 |
$606 |
| 2014-03-31 |
$605 |
| 2013-12-31 |
$681 |
| 2013-09-30 |
$666 |
| 2013-06-30 |
$595 |
| 2013-03-31 |
$592 |
| 2012-12-31 |
$369 |
| 2012-09-30 |
$384 |
| 2012-06-30 |
$399 |
| 2012-03-31 |
$218 |
| 2011-12-31 |
$259 |
| 2011-09-30 |
$283 |
| 2011-06-30 |
$303 |
| 2011-03-31 |
$315 |
| 2010-12-31 |
$331 |
| 2010-09-30 |
$213 |
| 2010-06-30 |
$232 |
| 2010-03-31 |
$250 |
| 2009-12-31 |
$181 |
| 2009-09-30 |
$183 |
| 2009-06-30 |
$206 |
| 2009-03-31 |
$215 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.136B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
